Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.56 |
| ▸ | PPARA | Q07869 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2978389 | 1.00 | PPARG (0.56) | PPARGPPARAALDH1A1MEN1LMNA | |
| SCHEMBL475127 | 1.00 | PPARG (0.56) | PPARGPPARAALDH1A1MEN1LMNA | |
| SCHEMBL13994554 | 0.93 | PPARG (0.50) | PPARGPPARAALDH1A1MEN1LMNA | |
| SCHEMBL13994555 | 0.91 | PPARG (0.49) | PPARGPPARAALDH1A1MEN1LMNA | |
| SCHEMBL2978823 | 0.91 | PPARG (0.52) | PPARGPPARAALDH1A1NPC1RAB9A | |
| SCHEMBL2353696 | 0.91 | PPARG (0.54) | PPARGPPARAALDH1A1MEN1LMNA | |
| SCHEMBL2353699 | 0.91 | PPARG (0.54) | PPARGPPARAALDH1A1MEN1LMNA | |
| SCHEMBL2719920 | 0.91 | PPARG (0.52) | PPARGPPARAALDH1A1NPC1RAB9A | |
| SCHEMBL2980280 | 0.91 | PPARG (0.52) | PPARGPPARAALDH1A1MEN1LMNA | |
| SCHEMBL13994557 | 0.91 | PPARG (0.61) | PPARGPPARANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412705-B1 | NOVEL THERAPEUTIC AGENT FOR COGNITIVE IMPAIRMENT | DAINIPPON SUMITOMO PHARMA CO (JP) | 2014-05-07 | — | — | EP | claimed |
| EP-2412705-A1 | NOVEL THERAPEUTIC AGENT FOR COGNITIVE IMPAIRMENT | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-02-01 | — | — | EP | claimed |
| US-20120010264-A1 | NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-01-12 | — | — | US | claimed |
| US-20110212892-A1 | AGENT FOR TREATMENT OF DIABETES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-01 | — | — | US | claimed |
| EP-2351563-A1 | AGENT FOR TREATMENT OF DIABETES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-08-03 | — | — | EP | claimed |
| EP-2412705-B1 | NOVEL THERAPEUTIC AGENT FOR COGNITIVE IMPAIRMENT | DAINIPPON SUMITOMO PHARMA CO (JP) | 2014-05-07 | — | — | EP | disclosed |
| EP-1647546-B1 | NOVEL HETEROARYL DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| CN-102365269-A | Novel drugs for the treatment of cognitive impairment | DAINIPPON SUMITOMO PHARMA CO | 2012-02-29 | — | — | CN | disclosed |
| EP-2412705-A1 | NOVEL THERAPEUTIC AGENT FOR COGNITIVE IMPAIRMENT | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| EP-2412705-A1 | NOVEL THERAPEUTIC AGENT FOR COGNITIVE IMPAIRMENT | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120010264-A1 | NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010264-A1 | NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| WO-2010050422-A1 | AGENT FOR TREATMENT OF DIABETES | 大日本住友製薬株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-20060194857-A1 | Novel heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1647546-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212892-A1 | AGENT FOR TREATMENT OF DIABETES | SLC5A1, GLP1R, SLC5A2 | PPARG 62/4885PPARA 16/4885ALDH1A1 291/4885 |
| US-20060194857-A1 | Novel heteroaryl derivative | NR0B1, UGT1A10, NR0B2 | PPARG 282/4885PPARA 411/4885ALDH1A1 552/4885 |
| US-20120010264-A1 | NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | PSEN2, PSEN1, GRIK5 | PPARG 291/4885PPARA 256/4885ALDH1A1 2642/4885 |
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | PPARG 498/4885PPARA 561/4885ALDH1A1 699/4885 |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | NR0B1, UGT1A10, NR0B2 | PPARG 282/4885PPARA 411/4885ALDH1A1 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.